• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pixie Dust Technologies, Inc. Announces Fiscal Year 2024 Financial Results

    8/22/24 4:15:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PXDT alert in real time by email

    NEW YORK and TOKYO, Aug. 22, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology, today announced its financial results for the fiscal year ended April 30, 2024.

    Pixie Dust Technologies logo (CNW Group/Pixie Dust Technologies)

    Fiscal Year Financial Results

    The Company's audited financial statements for the fiscal year ended April 30, 2024 and the related notes, and related management's discussion and analysis of the Company's financial condition and results of operations can be found in the Company's Annual Report on Form 20-F filed with the SEC, a copy of which can also be found on the Company's website. The Company's functional currency and reporting currency is the Japanese yen (which we refer to as "JPY" or "¥"). The terms "dollar," "USD," "US$" or "$" refer to U.S. dollars, the legal currency of the United States. Convenience conversions provided in this press release of Japanese yen into U.S. dollars have been made at the exchange rate of ¥157.54 US$1.00, which was the foreign exchange rate on April 30, 2024 as reported by the Board of Governors of the Federal Reserve System. All figures are expressed in Japanese Yen and United States dollars unless otherwise stated.

    • Total Revenue increased by 40.9% from ¥704,712 thousand in the fiscal year ended April 30, 2023 to ¥993,021 thousand ($6,303 thousand) in the fiscal year ended April 30, 2024, primarily due to increases in product revenue of ¥340,205 thousand, partially offset by a decrease in commissioned research and development of ¥23,433 thousand with the remaining decrease being predominately due to decreases in solution service.
    • Product Sales were ¥523,154 thousand ($3,320 thousand) in the fiscal year ended April 30, 2024, representing a 186.0% increase from the prior year. This increase is primarily attributed to the sales of the following products: kikippa (launched in April 2023), SonoRepro (launched in November 2022) and iwasemi (launched in July 2022).
    • Services Sales declined to ¥469,867 thousand ($2,983 thousand) in the fiscal year ended April 30, 2024 from ¥521,763 thousand in the prior year. This decline in services is primarily due to our decision to reallocate resources to product sales.
    • Research and Development Expenses declined by 25.3% from ¥686,557 thousand in fiscal year 2023 ended April 30, 2023 to ¥512,997 thousand ($3,256 thousand) in the fiscal year ended April 30, 2024. This decline is primarily due to a shift in focus from the research and development of kikippa and VUEVO to product commercialization.
    • Selling, General and Administrative Expenses increased by 16.2% from ¥1,856,056 thousand for the fiscal year ended April 30, 2023 to ¥2,155,860 thousand ($13,684 thousand) for the fiscal year ended April 30, 2024, mainly due to increases in marketing promotion expenses and personnel costs for sales and marketing staff as we expand our marketing and sales efforts for our products, with the remaining increase related to rent expense and depreciation expenses in connection with transferring to our new headquarters.
    • Our other income, net increased by 47.4% from ¥43,798 thousand for the fiscal year ended April 30, 2023 to ¥64,567 thousand ($409 thousand) for the fiscal year ended April 30, 2024, primarily due to an increase in foreign exchange remeasurement gains on cash held in U.S. dollars as a result of the receipt of the net proceeds from the initial public offering of our ADSs, as well as a gain related to the change in fair value of warrants liability, partially offset by a decrease in insurance proceeds. During the year ended April 30, 2023, we received insurance proceeds related to a claim for losses that occurred in the year ended April 30, 2022. There were no such proceeds during the year ended April 30, 2024.
    • Net loss. We have incurred significant operating losses to date and negative cash flows since our inception. We incurred net loss of ¥1,965,491 thousand for the year ended April 30, 2023, and ¥1,974,536 thousand ($12,534 thousand) for the year ended April 30, 2024. As of April 30, 2024, we had an accumulated deficit of ¥6,356,788 thousand ($40,350 thousand). Our primary use of capital resources has been to conduct research and development activities, expand our marketing and sales efforts for our products, organize and staff our Company, develop our business plan, secure related intellectual property rights, and raise capital.
    • Our principal sources of liquidity were cash and cash equivalents totaling ¥2,135,513 thousand as of April 30, 2023 and ¥1,607,763 thousand ($10,205 thousand) as of April 30, 2024, which were held and used for working capital purposes. Our cash and cash equivalents are comprised of cash on hand, demand deposits, and time deposits maintained at various financial institutions.

    Forward-Looking Statements

    Certain statements contained in this press release, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include projections and estimates concerning our possible or assumed future results of operations, financial condition, business strategies and plans, market opportunity, competitive position, industry environment, and potential growth opportunities. In some cases, you can identify forward-looking statements by terms such as "may", "will", "should", "believe", "expect", "could", "intend", "plan", "anticipate", "estimate", "continue", "predict", "project", "potential", "target," "goal" or other words that convey the uncertainty of future events or outcomes. You can also identify forward-looking statements by discussions of strategy, plans or intentions. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, because forward-looking statements relate to matters that have not yet occurred, they are inherently subject to significant business, competitive, economic, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. These and other important factors, including, among others, those discussed in our most recent annual report for the fiscal year ending April 30, 2024, filed under cover of Form 20-F with U.S. Securities and Exchange Commission, under the headings "Risk Factors","Operating and Financial Review and Prospects", and "Business Overview" may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements in this annual report. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include our expectations regarding our revenue, expenses, and other operating results.

    About Pixie Dust Technologies, Inc.

    Pixie Dust Technologies, Inc. is a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology. The Company is currently focusing on two areas of product development: (1) "Personal Care & Diversity", where wave control technology is applied to mechanobiology and intervention/assistance in vision, hearing, and touch, and (2) "Workspace & Digital Transformation," where metamaterials (technology that creates properties through structure rather than material) and solutions to commercial design problems, such as in offices or construction sites, are applied.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pixie-dust-technologies-inc-announces-fiscal-year-2024-financial-results-302227329.html

    SOURCE Pixie Dust Technologies

    Get the next $PXDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PXDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXDT
    Financials

    Live finance-specific insights

    See more
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CORRECTION: Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 12, 2024

      NEW YORK and TOKYO, Feb. 11, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Monday, February 12, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/11/24 12:48:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 13, 2024

      NEW YORK and TOKYO, Feb. 6, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Tuesday, February 13, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/6/24 9:00:00 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • /C O R R E C T I O N -- Pixie Dust Technologies/

      This release is announcing the amendment of the press release originally issued on October 23, 2024 to disclose the effective date of the delisting from NASDAQ and the Form 15-F filing from November 15, 2024, to November 14, 2024, wherever the date appears. Additionally, trading of the Company's American Depositary Receipts ("ADRs") on NASDAQ will be suspended effective prior to trading on November 14, 2024. No other changes have been made to the original press release. (Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission. NEW YORK and TOKYO, Oct. 24, 2024 /PRNewswire/ - Pixie Dust Te

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.

      NEW YORK and TOKYO, Oct. 23, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (the "Company") announced that its board of directors resolved, at its meeting held on October 23, 2024, to delist its American Depositary Receipts ("ADRs") from the NASDAQ Capital Market ("NASDAQ") and submit an application for deregistration with the U.S. Securities and Exchange Commission ("SEC"). The Company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. Plans regarding the delisting and deregistration are as follows: 1.                  Reasons for Applying for Delisting The Company listed its ADRs on NASDAQ in August 2023 to access the U.S. capital markets an

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Pixie Dust Technologies Announces CFO Transition

      NEW YORK and TOKYO, March 13, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, announced the appointment of Nobuhiro Takagi and Nobufusa Tarumi as co-Chief Financial Officer ("co-CFO"), effective March 13, 2024. Messrs. Takagi and Tarumi succeed Mr. Mamoru Miwa, whose resignation was not the result of any disagreement or conflict with the Company, its operations, policies, or practices. The role of the Company's Chief Accounting Officer ("CAO"), previously held by Nobuhiro Takagi, will be assumed by the co-CFOs.

      3/13/24 4:05:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:11:11 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:08:59 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:06:35 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    SEC Filings

    See more
    • SEC Form 6-K filed by Pixie Dust Technologies Inc.

      6-K - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/25/24 8:00:20 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Pixie Dust Technologies Inc.

      25 - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/4/24 4:30:02 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.

      6-K/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      10/24/24 1:55:49 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care